CTMC, a joint venture between Resilience and MD Anderson Cancer Center, has partnered with Einstein Hospital Israelita in Sao Paulo, Brazil, to expand access to cell therapies across Latin America. The collaboration establishes Einstein as the first international member of the CTMC Network Alliance, a program designed to accelerate cell therapy adoption globally.

Amy Hay, chief business officer of CTMC, said: “The CTMC Network Alliance program creates value through sharing of proprietary reagents, in-depth training programs and ongoing strategic alignment with the intent of increasing access to cell therapy globally. With CTMC’s experience, we are in a unique position to aggregate leadership in cell therapy to form a global community focused on democratizing access to transformative cell therapies.”

Einstein Hospital Israelita, the top-ranked hospital in Latin America and 22nd globally according to Newsweek, was the first in the region to provide CAR-T and CAR NK cell therapies. Dr. Lucila Kerbauy, a hematologist at Einstein trained at MD Anderson, is leading efforts to expand patient access and accelerate translational research in TIL therapy.

The Latin American cell therapy market earned over $46 million in 2023 and is projected to grow at 15% annually, reaching $129 million in five years. Brazil accounts for over half of regional activity, but access remains limited — more than 90% of patients currently cannot access cellular therapies due to infrastructure and staffing gaps.

Sidney Klajner, president of Einstein, said: “Einstein has always been at the forefront of medicine, being a pioneer in Latin America in offering therapies such as CAR-T and CAR-NK cells. Now, alongside the CTMC Network Alliance, we will take an even greater leap, building a center of excellence in precision medicine that will benefit not only Brazil, but the entire region.”

Jason Bock, CEO of CTMC, added: “Cell therapy democratization requires collaboration on a global basis. By working with Alliance members, we can accelerate their ability to develop local processing and manufacturing. We are proud to have Einstein as our first Alliance member and are eager to share our deep knowledge of the development and manufacture of TIL therapies.”

The Alliance will provide hospitals worldwide with guidance on establishing local cell therapy centers, integrating patient-adjacent manufacturing with clinical care, and offering access to education, standards, and proprietary reagents. The aim is to build a global network that expands patient access to cell therapies and drives collaboration across discovery, translational research, and clinical application.